Purpura, Thrombotic Thrombocytopenic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Thrombotic thrombocytopenic purpura (TTP) is a rare life threatening thrombotic microangiopathy caused by a severe functional deficiency of ADAMTS13, most frequently due to autoantibodies to ADAMTS13, thus termed acquired autoimmune TTP.
|
31330376 |
2019 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In contrast, disseminated intravascular microthrombosis (DIT) occurs in thrombotic thrombocytopenic purpura (TTP) and TTP-like syndrome due to ADAMTS13 deficiency or insufficiency.
|
29621007 |
2018 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The lack of ADAMTS13 expression in the plasma from patients with hereditary TTP may indicate defective synthesis, impaired cellular secretion, or enhanced degradation in the circulation.
|
17187257 |
2007 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
Biomarker
|
disease |
BEFREE |
In patients with clinical presentations of TMAs, having an in-hospital ADAMTS13 test to promptly establish the diagnosis of TTP appears to be cost-effective.
|
28646526 |
2017 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Thrombotic thrombocytopenic purpura (TTP) is a severe disease associated with unusually large, hemostatically hyperactive von Willebrand factor (VWF) and severe deficiency in ADAMTS-13, the protease responsible for the proteolytic degradation of VWF in plasma.
|
14727256 |
2004 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
Biomarker
|
disease |
BEFREE |
TTP is most commonly associated with deficiency or inhibition of von Willebrand factor-cleaving protease (ADAMTS13) activity.
|
24401653 |
2014 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
TTP can be inherited due to deficiencies in the activity of von Willebrand factor cleaving protease (ADAMTS13) or acquired due to the presence of autoantibodies directed against ADAMTS13.
|
21252531 |
2011 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
For thrombotic microangiopathies (TMAs), the diagnosis of atypical hemolytic uremic syndrome (aHUS) is made by ruling out Shiga toxin-producing Escherichia coli (STEC)-associated HUS and ADAMTS13 activity-deficient thrombotic thrombocytopenic purpura (TTP), often using the exclusion criteria for secondary TMAs.
|
25951460 |
2015 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
Biomarker
|
disease |
BEFREE |
The short-term prognostic usefulness of ADAMTS13 testing during acute TTP warrants further investigation because of limited prospective studies (Ferrari S et al., Blood 2007;109:2815-2822; Peyvandi et al., Haematologica 2008;93:232-239).
|
18756543 |
2008 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Peripheral blood from 38 well-characterized patients with autoimmune ADAMTS13-deficient TTP in remission was examined for autoantibodies and global gene expression.
|
25671313 |
2015 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
Biomarker
|
disease |
BEFREE |
ADAMTS13-specific CICs seem to be able to predict the recurrence of acute TTP episodes in the first 2years after disease onset.
|
27887777 |
2017 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Objectives To identify all patients with hereditary TTP in central Norway and to investigate the prevalence of hereditary TTP and the population frequencies of two common ADAMTS-13 mutations.
|
26566785 |
2016 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Implementation of a rapid assay of ADAMTS13 activity was associated with improved 30-day survival rate in patients with acquired primary thrombotic thrombocytopenic purpura who received platelet transfusions.
|
28500622 |
2017 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Finally, our assay was able to determine kinetic changes of plasma levels of anti-ADAMTS13 IgGs in TTP patients during plasma therapy.
|
21901237 |
2011 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Deficiency of ADAMTS13 is found in patients with thrombotic thrombocytopenic purpura (TTP), and the genetic defects in the ADAMTS13 gene or the autoantibody against ADAMTS13 is thought to be responsible for the development of TTP.
|
16189276 |
2006 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Severe ADAMTS13 deficiency in thrombotic thrombocytopenic purpura (TTP) is either constitutional and caused by ADAMTS13 mutations, or acquired and most often due to ADAMTS13 inhibitory autoantibodies.
|
15367436 |
2005 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
Biomarker
|
disease |
BEFREE |
ADAMTS13--more than just TMA and TTP.
|
21531732 |
2011 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Secondly, risk stratification by means of ADAMTS13 deficiency and ADAMTS13 antibodies might lead to a more tailored approach in treating TTP patients.
|
19851089 |
2010 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies.
|
29567368 |
2018 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we determined ADAMTS13 activity and FVL carrier-ship in 256 consecutive patients presenting with various forms of acute TMA, including patients diagnosed with TTP or hemolytic-uremic syndrome (HUS).
|
16411392 |
2005 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
Biomarker
|
disease |
BEFREE |
This article reviews the role of this cleavage in regulating vWF-platelet interaction and proposes a scheme for understanding how a deficiency of ADAMTS13 results in the development of microthrombi in patients with thrombotic thrombocytopenic purpura.
|
12615692 |
2003 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Sequence analysis of the ADAMTS13 locus of 2 patients with hereditary thrombotic thrombocytopenic purpura (TTP) revealed the homozygous presence of 4 single nucleotide polymorphisms (SNPs) (R7W, Q448E, P618A, A732V) and a rare missense mutation (R1336W).
|
16160007 |
2006 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Click to hear Dr Cataland's presentation on acquired thrombotic thrombocytopenic purpura SUMMARY: Background Acquired thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening thrombotic microangiopathy associated with the development of autoantibodies against the von Willebrand factor-cleaving protease ADAMTS-13.
|
27762046 |
2016 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Obesity, which is associated with enhanced ADAMTS13 levels is nevertheless considered to be an independent risk factor for TTP.
|
25813552 |
2015 |
Purpura, Thrombotic Thrombocytopenic
|
0.700 |
Biomarker
|
disease |
BEFREE |
This article will point out that the measurement of ADAMTS13 is able to diagnose accurately the majority of TTP cases, and that very simple tests such as the platelet count and serum creatinine can predict the deficiency of the protease with a good degree of accuracy.
|
26386489 |
2015 |